Technical Analysis for CNTA - Centessa Pharmaceuticals plc

Grade Last Price % Change Price Change
C 10.62 -1.21% -0.13
CNTA closed down 1.21 percent on Monday, March 18, 2024, on 60 percent of normal volume.
Earnings due: Mar 28
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Resistance Bearish -1.21%
New Downtrend Bearish -1.21%
Bollinger Band Squeeze Range Contraction -1.21%
Outside Day Range Expansion -1.21%
Fell Below 20 DMA Bearish 1.43%
Bollinger Band Squeeze Range Contraction 1.43%
20 DMA Support Bullish -2.12%
Bollinger Band Squeeze Range Contraction -2.12%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 17 hours ago
Up 1% about 17 hours ago
Rose Above 20 DMA about 17 hours ago
20 DMA Support about 17 hours ago
10 DMA Support about 17 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Centessa Pharmaceuticals plc Description

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Pharmaceutical Solid Tumors Drugs Immunotherapy Non Small Cell Lung Cancer Lung Cancer Epidermal Growth Factor Receptor Orphan Drug Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Oncogenes Hematological Malignancies Lupus Narcolepsy Non Small Cell Lung Carcinoma Alpha 1 Antitrypsin Deficiency Hemophilia A Treatment Of Hemophilia Autosomal Dominant Polycystic Kidney Disease Cutaneous Squamous Cell Carcinoma Systemic Sclerosis

Is CNTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.95
52 Week Low 3.38
Average Volume 447,305
200-Day Moving Average 7.26
50-Day Moving Average 9.25
20-Day Moving Average 10.79
10-Day Moving Average 10.73
Average True Range 0.73
RSI (14) 53.27
ADX 24.71
+DI 21.16
-DI 21.85
Chandelier Exit (Long, 3 ATRs) 9.77
Chandelier Exit (Short, 3 ATRs) 11.89
Upper Bollinger Bands 11.51
Lower Bollinger Band 10.07
Percent B (%b) 0.38
BandWidth 13.28
MACD Line 0.36
MACD Signal Line 0.50
MACD Histogram -0.1395
Fundamentals Value
Market Cap 1.04 Billion
Num Shares 97.6 Million
EPS -1.65
Price-to-Earnings (P/E) Ratio -6.44
Price-to-Sales 0.00
Price-to-Book 2.81
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.61
Resistance 3 (R3) 11.60 11.27 11.45
Resistance 2 (R2) 11.27 11.01 11.27 11.39
Resistance 1 (R1) 10.94 10.86 10.78 10.95 11.33
Pivot Point 10.61 10.61 10.52 10.61 10.61
Support 1 (S1) 10.28 10.35 10.12 10.29 9.91
Support 2 (S2) 9.95 10.20 9.95 9.85
Support 3 (S3) 9.62 9.95 9.80
Support 4 (S4) 9.63